|
US6765087B1
(en)
*
|
1992-08-21 |
2004-07-20 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
|
EP0739981A1
(de)
*
|
1995-04-25 |
1996-10-30 |
Vrije Universiteit Brussel |
Variable Fragmente von Immunglobulinen-Verwendung zur therapeutischen oder veterinären Zwecken
|
|
US20040248201A1
(en)
*
|
1996-06-27 |
2004-12-09 |
Serge Muyldermans |
Recognition molecules interacting specifically with the active site or cleft of a target molecule
|
|
GB9620093D0
(en)
*
|
1996-09-26 |
1996-11-13 |
Unilever Plc |
Photofading inhibitor derivatives and their use in fabric treatment compositions
|
|
CA2293304A1
(en)
*
|
1997-06-13 |
1998-12-17 |
Unilever Plc |
Bleaching enzymes
|
|
US6670453B2
(en)
|
1997-10-27 |
2003-12-30 |
Unilever Patent Holdings B.V. |
Multivalent antigen-binding proteins
|
|
EP0954978B1
(de)
*
|
1998-03-12 |
2011-11-30 |
VHsquared Limited |
Produkten die inaktivierte Hefen oder Schimmel enthalten, die auf ihrer Aussenoberfläche aktive Antikörper haben
|
|
ATE535154T1
(de)
|
1998-03-12 |
2011-12-15 |
Vhsquared Ltd |
Produkten die inaktivierte hefen oder schimmel enthalten, die auf ihrer aussenoberfläche aktive antikörper haben
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
CA2354908A1
(en)
*
|
1998-12-11 |
2000-06-22 |
Unilever Plc |
Bleaching enzymes and detergent compositions comprising them
|
|
EP1144616B2
(de)
*
|
1999-01-19 |
2009-01-14 |
Unilever Plc |
Verfahren zur herstellung von antikörperfragmenten
|
|
WO2004009618A2
(en)
|
2002-07-18 |
2004-01-29 |
Crucell Holland B.V. |
Recombinant production of mixtures of antibodies
|
|
AP1447A
(en)
*
|
1999-04-22 |
2005-08-12 |
Unilever Plc |
Inhibition of viral infection using monovalent antigen-binding proteins.
|
|
AU6153100A
(en)
|
1999-07-27 |
2001-02-13 |
Davis, Paul James |
Bleaching detergent compositions
|
|
EP1118669A3
(de)
*
|
1999-12-17 |
2001-08-29 |
Unilever Plc |
Herstellung von Camelid-Antikörpern in Pflanzen
|
|
EP1246898B1
(de)
|
1999-12-22 |
2005-10-26 |
Unilever N.V. |
Verfahren zur behandlung von gewebe
|
|
TR200401275T4
(tr)
|
1999-12-22 |
2004-07-21 |
Unilever N.V. |
Kumaşların muamele edilmesi için yöntem ve bu yöntemde kullanılan aygıt
|
|
WO2001046357A2
(en)
*
|
1999-12-22 |
2001-06-28 |
Unilever N.V. |
Detergent compositions comprising benefit agents
|
|
EP1242572A2
(de)
|
1999-12-22 |
2002-09-25 |
Unilever N.V. |
Verfahren zum einbringen eines wirkstoffes
|
|
EP1479694B1
(de)
|
1999-12-28 |
2016-10-26 |
ESBATech, an Alcon Biomedical Research Unit LLC |
ScFv Intrakörper mit definierter Struktur ("Framework"), der in einer reduzierenden Umgebung stabil ist
|
|
EP1134231B1
(de)
*
|
2000-03-14 |
2009-04-15 |
Unilever N.V. |
Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen
|
|
CA2429544C
(en)
|
2000-11-17 |
2010-10-19 |
University Of Rochester |
In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
|
|
WO2002048193A2
(en)
*
|
2000-12-13 |
2002-06-20 |
Unilever N.V. |
Camelidae antibody arrays
|
|
AU2002235761A1
(en)
|
2000-12-19 |
2002-07-01 |
Unilever Plc |
Stabilization of antibodies or fragments thereof
|
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
EP2281837B1
(de)
|
2001-08-10 |
2016-10-05 |
Aberdeen University |
Antigenbindende domäne aus fisch
|
|
JP2005289809A
(ja)
*
|
2001-10-24 |
2005-10-20 |
Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) |
突然変異重鎖抗体
|
|
EP1318195A1
(de)
*
|
2001-12-10 |
2003-06-11 |
CatchMabs B.V. |
Ein Struktur für die Präsentation erwünschter Peptidsequenzen
|
|
AU2003205615B2
(en)
|
2002-01-10 |
2008-09-25 |
Universiteit Gent |
A novel splice variant of MyD88 and uses thereof
|
|
EP1463512B1
(de)
|
2002-01-11 |
2014-05-28 |
biOasis Technologies Inc. |
Verwendung von p97 als enzym-abgabesystem zur abgabe von therapeutischen lysosomalen enzymen
|
|
US20040018573A1
(en)
*
|
2002-04-18 |
2004-01-29 |
Power Scott D |
Production of functional antibodies in filamentous fungi
|
|
MX337052B
(es)
|
2002-07-15 |
2016-02-11 |
Univ Texas |
Peptidos que se enlazan a fosfatidiletanolamina y sus usos en el tratamiento de infecciones virales y del cancer.
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
WO2004015425A1
(en)
|
2002-08-07 |
2004-02-19 |
Umc Utrecht Holding B.V. |
Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
|
|
AU2003262650B2
(en)
|
2002-08-14 |
2009-10-29 |
Macrogenics, Inc. |
FcgammaRIIB-specific antibodies and methods of use thereof
|
|
WO2004025263A2
(en)
*
|
2002-09-16 |
2004-03-25 |
Advanced Bionutrition Corporation |
Protein and peptide expression for passive immunity
|
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
|
US20060034845A1
(en)
|
2002-11-08 |
2006-02-16 |
Karen Silence |
Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
|
|
EP2284192A3
(de)
*
|
2002-11-08 |
2011-07-20 |
Ablynx N.V. |
Antikörper aus Camelidae zur sublingualen Verabreichung
|
|
US6974860B2
(en)
*
|
2002-12-30 |
2005-12-13 |
Kimberly-Clark Worldwide, Inc. |
Target recognizing binding agents
|
|
CN100439400C
(zh)
|
2003-01-10 |
2008-12-03 |
埃博灵克斯股份有限公司 |
治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
|
|
WO2004069872A1
(en)
*
|
2003-02-06 |
2004-08-19 |
Novozymes A/S |
Human heavy chain antibody expression in filamentous fungi
|
|
WO2004091510A2
(en)
|
2003-04-11 |
2004-10-28 |
Medimmune, Inc. |
Recombinant il-9 antibodies and uses thereof
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
EP1639009B1
(de)
|
2003-05-30 |
2013-02-27 |
Merus B.V. |
Fab-bibliothek zur herstellung von einer mischung von antikörpern
|
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
US20050221383A1
(en)
|
2003-08-08 |
2005-10-06 |
Choong-Chin Liew |
Osteoarthritis biomarkers and uses thereof
|
|
DK3718564T3
(da)
|
2003-12-23 |
2023-11-06 |
Genentech Inc |
Nye anti-IL-13-antistoffer og anvendelser
|
|
CA2554054C
(en)
|
2004-01-20 |
2013-06-04 |
Merus B.V. |
Mixtures of binding proteins
|
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
|
EP1751181B1
(de)
|
2004-06-02 |
2012-08-15 |
AdAlta Pty Ltd |
Auf haifisch-ignar-domänen basierende bindungseinheiten
|
|
EP1750759A4
(de)
*
|
2004-06-04 |
2008-06-04 |
Genencor Int |
Screeningverfahren unter verwendung von antikörper schweren ketten
|
|
AU2005299355A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Llc |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
|
FR2879605B1
(fr)
*
|
2004-12-16 |
2008-10-17 |
Centre Nat Rech Scient Cnrse |
Production de formats d'anticorps et applications immunologiques de ces formats
|
|
DE602006015281D1
(de)
|
2005-01-14 |
2010-08-19 |
Ablynx Nv |
Verfahren und testvorrichtungen zur unterscheidung verschiedener formen von krankheiten und leiden, die durch thrombocytopenia und/oder durch spontane interaktionen zwischen dem von-willebrand-faktor und plättchen gekennzeichnet sind
|
|
EP2520669A3
(de)
|
2005-02-07 |
2013-02-27 |
GeneNews Inc. |
Biomarker für milde Arthrose und Verwendungen davon
|
|
EP1855694B1
(de)
|
2005-02-09 |
2020-12-02 |
Sarepta Therapeutics, Inc. |
Antisense-zusammensetzung zur behandlung von muskelatrophie
|
|
BR122013001996B1
(pt)
|
2005-05-18 |
2022-02-01 |
Ablynx N.V. |
Nanocorpos melhorados contra fator alfa de necrose tumoral
|
|
RU2433139C2
(ru)
|
2005-05-20 |
2011-11-10 |
Аблинкс Н.В. |
Nanobodies tm для лечения заболеваний, опосредованных агрегацией
|
|
DE102005023617A1
(de)
|
2005-05-21 |
2006-11-23 |
Aspre Ag |
Verfahren zum Mischen von Farben in einem Display
|
|
EP1912675B1
(de)
|
2005-07-25 |
2014-02-12 |
Emergent Product Development Seattle, LLC |
B-zell-verringerung mit cd37-spezifischen und cd20-spezifischen bindungsmolekülen
|
|
CA2619748C
(en)
|
2005-08-30 |
2016-06-14 |
Actogenix Nv |
Novel treatment of chronic enterocolitis
|
|
PL1931710T3
(pl)
|
2005-08-31 |
2017-06-30 |
Merck Sharp & Dohme Corp. |
Przeciwciała anty-il-23 skonstruowane techniką inżynierii genetycznej
|
|
ATE445415T1
(de)
|
2005-09-01 |
2009-10-15 |
Schering Corp |
Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
|
|
TW200730825A
(en)
|
2005-10-21 |
2007-08-16 |
Genenews Inc |
Method and apparatus for correlating levels of biomarker products with disease
|
|
JP2009514888A
(ja)
|
2005-11-04 |
2009-04-09 |
ジェネンテック・インコーポレーテッド |
眼疾患を処置するための補体経路の阻害剤の使用
|
|
EP1983823A1
(de)
|
2006-01-17 |
2008-10-29 |
VIB vzw |
Hemmer der prolyl-hydroxylase 1 für die behandlung von skelettmuskeldegeneration
|
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
|
|
EP1999147A1
(de)
*
|
2006-03-27 |
2008-12-10 |
Ablynx N.V. |
Medizinisches verabreichungsgerät für therapeutische proteine auf der basis von einzeldomänantikörpern
|
|
JP2009536527A
(ja)
*
|
2006-05-09 |
2009-10-15 |
ジェネンテック・インコーポレーテッド |
最適化されたスキャフォールドを備えた結合ポリペプチド
|
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
|
WO2010123874A1
(en)
|
2009-04-20 |
2010-10-28 |
Oxford Biotherapeutics Ltd. |
Antibodies specific to cadherin-17
|
|
EP2041178A2
(de)
|
2006-06-12 |
2009-04-01 |
Trubion Pharmaceuticals, Inc. |
Multivalente einzelkettenbindungsproteine mit effektorfunktion
|
|
EP2815764A1
(de)
|
2006-06-14 |
2014-12-24 |
Macrogenics, Inc. |
Verfahren zur Behandlung von Autoimmunerkrankungen anhand von monoklonalen Antikörpern mit reduzierter Toxizität
|
|
US8874380B2
(en)
|
2010-12-09 |
2014-10-28 |
Rutgers, The State University Of New Jersey |
Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
|
|
SI2029173T1
(sl)
|
2006-06-26 |
2016-12-30 |
Macrogenics, Inc. |
Protitelesa, specifična za Fc RIIB, in postopki za njihovo uporabo
|
|
EP2292663B1
(de)
|
2006-08-28 |
2013-10-02 |
Kyowa Hakko Kirin Co., Ltd. |
Antagonistische humane monoklonale Antikörper spezifisch für humanes LIGHT
|
|
US20110182904A1
(en)
|
2006-09-05 |
2011-07-28 |
Deborah Zimmerman |
Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
|
|
JP5417175B2
(ja)
|
2006-10-02 |
2014-02-12 |
メダレックス・リミテッド・ライアビリティ・カンパニー |
Ｃｘｃｒ４に結合するヒト抗体およびその使用
|
|
HUE026042T2
(en)
|
2006-10-10 |
2016-05-30 |
Regenesance B V |
Complement inhibition for improved nerve regeneration
|
|
US8173423B2
(en)
|
2006-11-07 |
2012-05-08 |
Vib Vzw |
Diagnosis and treatment of T-cell acute lymphoblastic leukemia
|
|
CN103172743B
(zh)
|
2006-12-01 |
2015-04-08 |
梅达雷克斯有限责任公司 |
结合cd22的人抗体及其用途
|
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
|
JP5059119B2
(ja)
|
2006-12-14 |
2012-10-24 |
シェーリング コーポレイション |
操作された抗ｔｓｌｐ抗体
|
|
US20100150950A1
(en)
|
2006-12-14 |
2010-06-17 |
Medarex, Inc. |
Human antibodies that bind cd70 and uses thereof
|
|
TWI419904B
(zh)
|
2006-12-18 |
2013-12-21 |
Genentech Inc |
拮抗劑抗-ｎｏｔｃｈ３抗體及其用於預防及治療ｎｏｔｃｈ３相關疾病之用途
|
|
EP2102244A2
(de)
|
2006-12-19 |
2009-09-23 |
Ablynx N.V. |
Gegen metalloproteinase aus der adam-familie gerichtete aminosäuresequenzen und diese enthaltende polypeptide zur behandlung von mit adam in zusammenhang stehenden krankheiten und störungen
|
|
EP2115004A2
(de)
|
2006-12-19 |
2009-11-11 |
Ablynx N.V. |
Gegen gpcrs gerichtete aminosäuresequenzen und diese enthaltende polypeptide zur behandlung von mit gpcr in zusammenhang tehenden krankheiten und erkrankungen
|
|
MX2009009080A
(es)
|
2007-02-23 |
2009-11-02 |
Schering Corp |
Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
|
|
MX2009009079A
(es)
|
2007-02-23 |
2009-08-31 |
Schering Corp |
Anticuerpos anti-il-23p19 de ingenieria.
|
|
EP2447719B1
(de)
|
2007-02-26 |
2016-08-24 |
Oxford BioTherapeutics Ltd |
Proteine
|
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
|
MX2009009283A
(es)
|
2007-02-28 |
2009-11-18 |
Schering Corp |
Anticuerpos anti-interleuquina -23r de ingenieria.
|
|
CA2679400A1
(en)
|
2007-02-28 |
2008-09-04 |
Schering Corporation |
Combination therapy for treatment of immune disorders
|
|
AU2008226067B2
(en)
*
|
2007-03-12 |
2012-11-08 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Sequence based engineering and optimization of single chain antibodies
|
|
EP2308514B1
(de)
|
2007-03-23 |
2013-06-05 |
to-BBB Holding B.V. |
Konjugate zum Arzneimitteltransport über die Blut-Hirn-Schranke
|
|
EP2599791A1
(de)
|
2007-04-27 |
2013-06-05 |
Genentech, Inc. |
Starke, stabile und nicht immunsuppressive Anti-CD4-Antikörper
|
|
PT2164868E
(pt)
|
2007-05-04 |
2015-08-04 |
Technophage Investigaçao E Desenvolvimento Em Biotecnologia Sa |
Domínios variáveis de anticorpos de coelho manipulados e suas utilizações
|
|
NZ599278A
(en)
|
2007-05-14 |
2013-12-20 |
Medimmune Llc |
Methods of reducing eosinophil levels
|
|
CN103694351A
(zh)
|
2007-06-05 |
2014-04-02 |
耶鲁大学 |
受体酪氨酸激酶抑制剂及其使用方法
|
|
CN101849001B
(zh)
*
|
2007-06-25 |
2014-07-16 |
艾斯巴技术-诺华有限责任公司 |
修饰抗体的方法和具有改善的功能性质的修饰抗体
|
|
PL2164961T3
(pl)
*
|
2007-06-25 |
2015-08-31 |
Esbatech Alcon Biomed Res Unit |
Oparta na sekwencjach inżynieria i optymalizacja przeciwciał jednołańcuchowych
|
|
CA2691940C
(en)
|
2007-07-03 |
2018-03-06 |
Joost Alexander Kolkman |
Methods for providing improved immunoglobulin sequences
|
|
PL2188306T3
(pl)
*
|
2007-08-10 |
2017-01-31 |
Janssen Biotech, Inc. |
Fragmenty powstałe po cięciu immunoglobuliny jako wskaźniki choroby oraz kompozycje do ich wykrywania i wiązania
|
|
US8501907B2
(en)
|
2007-08-10 |
2013-08-06 |
Janssen Biotech, Inc. |
Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
|
|
BRPI0815983A2
(pt)
|
2007-08-29 |
2018-05-22 |
Sanofi Aventis |
anticorpos anti-cxcr5 humanizados, derivados dos mesmos e seus usos
|
|
EP2050764A1
(de)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Neues polyvalentes bispezifisches Antikörperformat und Verwendung
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
CA2702637A1
(en)
|
2007-10-22 |
2009-04-30 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
AU2008328784B2
(en)
|
2007-11-27 |
2014-03-27 |
Ablynx N.V. |
Immunoglobulin constructs
|
|
JP5490714B2
(ja)
|
2007-11-28 |
2014-05-14 |
メディミューン，エルエルシー |
タンパク質製剤
|
|
BRPI0820875B1
(pt)
|
2007-12-14 |
2021-10-19 |
Bristol-Myers Squibb Company |
Molécula de ligação isolada, anticorpo monoclonal humano, composição, molécula de ácido nucleico, vetor e célula hospedeira
|
|
AU2009212747B2
(en)
|
2008-01-31 |
2013-11-07 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Engineered antibody constant domain molecules
|
|
AU2009221106A1
(en)
|
2008-03-05 |
2009-09-11 |
Ablynx Nv |
Novel antigen binding dimer-complexes, methods of making and uses thereof
|
|
GB0809069D0
(en)
|
2008-05-19 |
2008-06-25 |
Univ Leuven Kath |
Gene signatures
|
|
EP2947097A1
(de)
|
2008-04-07 |
2015-11-25 |
Ablynx N.V. |
Gegen Notch-Signalwege gerichtete Aminosäuresequenzen und Verwendungen davon
|
|
PT2132228E
(pt)
|
2008-04-11 |
2011-10-11 |
Emergent Product Dev Seattle |
Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
|
|
EP2268668A1
(de)
|
2008-04-17 |
2011-01-05 |
Ablynx N.V. |
An serumproteine bindende peptide und verbindungen, konstrukte und polypeptide damit
|
|
WO2010011944A2
(en)
|
2008-07-25 |
2010-01-28 |
Wagner Richard W |
Protein screeing methods
|
|
US8163497B2
(en)
|
2008-09-07 |
2012-04-24 |
Glyconex Inc. |
Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
|
|
US20100092470A1
(en)
*
|
2008-09-22 |
2010-04-15 |
Icb International, Inc. |
Antibodies, analogs and uses thereof
|
|
US20100136584A1
(en)
*
|
2008-09-22 |
2010-06-03 |
Icb International, Inc. |
Methods for using antibodies and analogs thereof
|
|
MX2011006549A
(es)
|
2008-12-19 |
2011-07-20 |
Schering Corp |
Suplemento alimenticio para el cultivo de celula de mamifero y metodos de uso.
|
|
WO2010084408A2
(en)
|
2009-01-21 |
2010-07-29 |
Oxford Biotherapeutics Ltd. |
Pta089 protein
|
|
WO2010085590A1
(en)
|
2009-01-23 |
2010-07-29 |
Biosynexus Incorporated |
Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria
|
|
US20100189919A1
(en)
|
2009-01-27 |
2010-07-29 |
Xerox Corporation |
Imaging System And Process Using Monoclonal Antibodies
|
|
GB0903325D0
(en)
|
2009-02-26 |
2009-04-08 |
Univ Aberdeen |
Antibody molecules
|
|
EA028336B1
(ru)
|
2009-03-05 |
2017-11-30 |
МЕДАРЕКС Л.Л.Си. |
Полностью человеческие антитела, специфические в отношении cadm1
|
|
EP2403873A1
(de)
|
2009-03-05 |
2012-01-11 |
Ablynx N.V. |
Neue antigenbindende dimerkomplexe, verfahren zur herstellung/vermeidung und anwendungen davon
|
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
|
EP2411413B1
(de)
|
2009-03-23 |
2016-05-11 |
Quark Pharmaceuticals, Inc. |
Verbindungszusammensetzungen und verfahren zur behandlung von krebs und fibrotischen krankheiten
|
|
US8609101B2
(en)
|
2009-04-23 |
2013-12-17 |
Theraclone Sciences, Inc. |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
|
|
AU2010243551B2
(en)
|
2009-04-30 |
2015-03-26 |
Ablynx Nv |
Method for the production of domain antibodies
|
|
WO2011019423A2
(en)
|
2009-05-20 |
2011-02-17 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
|
ES2804450T3
(es)
|
2009-07-10 |
2021-02-08 |
Ablynx Nv |
Método para la producción de dominios variables
|
|
AR077594A1
(es)
|
2009-07-31 |
2011-09-07 |
Organon Nv |
Anticuerpos completamente humanos para btla (atenuante de linfocitos b y t)
|
|
EP3023438B1
(de)
|
2009-09-03 |
2020-03-11 |
Merck Sharp & Dohme Corp. |
Anti-gitr-antikörper
|
|
EP3725330A1
(de)
|
2009-09-03 |
2020-10-21 |
Ablynx N.V. |
Stabile formulierungen aus polypeptiden und verwendungen davon
|
|
WO2011047083A1
(en)
|
2009-10-13 |
2011-04-21 |
Oxford Biotherapeutics Ltd. |
Antibodies against epha10
|
|
WO2011046218A1
(ja)
*
|
2009-10-16 |
2011-04-21 |
株式会社カネカ |
抗体を生産するハンゼヌラ・ポリモルファ、それを用いた抗体の生産方法、およびそれにより得られる抗体
|
|
EP2496605A1
(de)
|
2009-11-02 |
2012-09-12 |
Oxford Biotherapeutics Ltd. |
Ror1 als therapeutisches und diagnostisches ziel
|
|
MX2012005180A
(es)
|
2009-11-04 |
2012-06-08 |
Merck Sharp & Dohme |
Anticuerpo anti-linfopoyetina estromal timica (anti-tslp) modificado por tecnicas de ingenieria genetica.
|
|
JP2013509869A
(ja)
|
2009-11-05 |
2013-03-21 |
ノバルティス アーゲー |
線維症の進行の予測用バイオマーカー
|
|
LT2954779T
(lt)
*
|
2009-12-10 |
2019-05-27 |
Regeneron Pharmaceuticals, Inc. |
Pelės, gaminančios sunkiosios grandinės antikūnus
|
|
WO2011084357A1
(en)
|
2009-12-17 |
2011-07-14 |
Schering Corporation |
Modulation of pilr to treat immune disorders
|
|
WO2011083140A1
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Immunoglobulin single variable domain directed against human cxcr4
|
|
CA2788993A1
(en)
|
2010-02-05 |
2011-08-11 |
Ablynx N.V. |
Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
|
|
AU2011214299B2
(en)
|
2010-02-11 |
2014-07-31 |
Ablynx Nv |
Methods and compositions for the preparation of aerosols
|
|
US9556273B2
(en)
|
2010-03-29 |
2017-01-31 |
Vib Vzw |
Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
|
|
US9101674B2
(en)
|
2010-03-29 |
2015-08-11 |
Vib Vzw |
Targeting and in vivo imaging of tumor-associated macrophages
|
|
AU2011249783B9
(en)
|
2010-05-06 |
2014-11-06 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (LRP6) antibodies
|
|
BR112012028326A2
(pt)
|
2010-05-06 |
2017-03-21 |
Novartis Ag |
anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
|
|
CN102242094A
(zh)
*
|
2010-05-14 |
2011-11-16 |
浙江大学 |
一种提高alpha半乳糖苷酶活力持续性的方法
|
|
WO2011161263A1
(en)
|
2010-06-25 |
2011-12-29 |
Ablynx Nv |
Pharmaceutical compositions for cutaneous administration
|
|
AU2011273360A1
(en)
|
2010-07-02 |
2013-02-07 |
Vib Vzw |
The role of Fragile X mental retardation gene and protein in cancer metastasis
|
|
GB201012845D0
(en)
|
2010-07-30 |
2010-09-15 |
Vib Vzw |
Inhibition of dicer function for treatment of cancer
|
|
ES2620255T3
(es)
|
2010-08-20 |
2017-06-28 |
Novartis Ag |
Anticuerpos para el receptor del factor de crecimiento epidérmico 3 (HER3)
|
|
EP4226935A3
(de)
|
2010-08-31 |
2023-09-06 |
Theraclone Sciences, Inc. |
Antikörper zur neutralisierung des humanen immundefizienzvirus (hiv)
|
|
HUE041958T2
(hu)
|
2010-09-09 |
2019-06-28 |
Pfizer |
4-IBB-t kötõ molekulák
|
|
EP2614085B1
(de)
|
2010-09-10 |
2016-04-20 |
Apexigen, Inc. |
Anti-il-1-antikörper und verfahren zu ihrer verwendung
|
|
GB201016864D0
(en)
|
2010-10-06 |
2010-11-17 |
Univ Aston |
Therapeutic methods
|
|
US20130261288A1
(en)
|
2010-10-29 |
2013-10-03 |
Ablynx N.V. |
Method for the production of immunoglobulin single variable domains
|
|
SG191233A1
(en)
|
2010-12-23 |
2013-07-31 |
Janssen Biotech Inc |
Active protease-resistant antibody fc mutants
|
|
EP2658869B1
(de)
|
2010-12-30 |
2019-06-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenbindende formate zur verwendung in therapeutischen behandlungen oder diagnosetests
|
|
WO2012103165A2
(en)
|
2011-01-26 |
2012-08-02 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
|
TW201244737A
(en)
|
2011-02-03 |
2012-11-16 |
Alexion Pharma Inc |
Use of an anti-CD200 antibody for prolonging the survival of allografts
|
|
EP2681243B1
(de)
|
2011-03-03 |
2018-09-05 |
Apexigen, Inc. |
Anti-il-6-rezeptor-antikörper und verfahren zu ihrer verwendung
|
|
AU2012225246B2
(en)
|
2011-03-10 |
2016-01-21 |
Omeros Corporation |
Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
|
|
WO2012124567A1
(ja)
*
|
2011-03-11 |
2012-09-20 |
株式会社カネカ |
Vps遺伝子が破壊されている酵母を用いる異種タンパク質の製造方法
|
|
AR085911A1
(es)
|
2011-03-16 |
2013-11-06 |
Sanofi Sa |
Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
|
|
WO2012130872A1
(en)
|
2011-03-28 |
2012-10-04 |
Ablynx Nv |
Method for producing solid formulations comprising immunoglobulin single variable domains
|
|
LT2691112T
(lt)
|
2011-03-31 |
2018-07-25 |
Merck Sharp & Dohme Corp. |
Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
EP3508500A1
(de)
|
2011-04-29 |
2019-07-10 |
Apexigen, Inc. |
Anti-cd40-antikörper und verfahren zur verwendung
|
|
US9534039B2
(en)
|
2011-05-09 |
2017-01-03 |
Ablynx N.V. |
Method for the production of immunoglobulin single variable domains
|
|
JP6400470B2
(ja)
|
2011-05-16 |
2018-10-03 |
ジェネロン（シャンハイ）コーポレイション リミテッド |
多重特異性Ｆａｂ融合タンパク質および使用法
|
|
CA2836468C
(en)
|
2011-05-17 |
2021-05-04 |
The Rockefeller University |
Human immunodeficiency virus neutralizing antibodies and methods of use thereof
|
|
CN108329391A
(zh)
|
2011-05-27 |
2018-07-27 |
埃博灵克斯股份有限公司 |
使用rankl结合肽抑制骨质吸收
|
|
WO2012166906A1
(en)
|
2011-05-31 |
2012-12-06 |
Massachusetts Institute Of Technology |
Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
|
|
JP2014525736A
(ja)
|
2011-06-23 |
2014-10-02 |
アブリンクス エン．ヴェー． |
ＩｇＥに対する免疫グロブリン単一可変ドメイン
|
|
JP6247209B2
(ja)
|
2011-06-28 |
2017-12-13 |
オックスフォード ビオトヘラペウトイクス エルティーディー． |
Ａｄｐリボシルシクラーゼ２に対する抗体
|
|
JP6113721B2
(ja)
|
2011-06-28 |
2017-04-12 |
オックスフォード ビオトヘラペウトイクス エルティーディー． |
治療標的及び診断標的
|
|
PL2717917T3
(pl)
|
2011-07-05 |
2016-12-30 |
|
Koniugaty p97 - przeciwciało
|
|
AU2012294673B2
(en)
|
2011-08-05 |
2015-11-26 |
Bioasis Technologies Inc. |
p97 fragments with transfer activity
|
|
WO2013025446A2
(en)
|
2011-08-12 |
2013-02-21 |
Omeros Corporation |
Anti-fzd10 monoclonal antibodies and methods for their use
|
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
WO2013041901A1
(en)
|
2011-09-20 |
2013-03-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preparing single domain antibody microarrays
|
|
US10138302B2
(en)
|
2011-09-23 |
2018-11-27 |
Ablynx N.V. |
Methods for treating rheumatoid arthritis by administering interleukin-6 receptor antibodies
|
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
|
US9575073B2
(en)
|
2011-10-10 |
2017-02-21 |
Rutgers, The State University Of New Jersey |
Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
|
|
RU2014122184A
(ru)
|
2011-11-02 |
2015-12-10 |
Апексиджен, Инк. |
Антитела к kdr и способы их применения
|
|
RU2014122602A
(ru)
|
2011-11-04 |
2015-12-10 |
Новартис Аг |
Конструкции на основе белка, родственного липопротеинам низкой плотности, 6(lrp6), и удлинителя полупериода существования
|
|
WO2013084148A2
(en)
|
2011-12-05 |
2013-06-13 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
|
US20130251703A1
(en)
|
2011-12-05 |
2013-09-26 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
|
|
CN104080480A
(zh)
|
2012-01-01 |
2014-10-01 |
奇比艾企业有限公司 |
用于选择性递送治疗剂和诊断剂的endo180靶向微粒
|
|
US10112987B2
(en)
|
2012-01-09 |
2018-10-30 |
Icb International, Inc. |
Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
|
|
US10112988B2
(en)
|
2012-01-09 |
2018-10-30 |
Icb International, Inc. |
Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
|
|
US8865870B2
(en)
|
2012-01-20 |
2014-10-21 |
Genzyme Corporation |
Anti-CXCR3 antibodies and methods of use thereof
|
|
US20150301068A1
(en)
|
2012-01-30 |
2015-10-22 |
Vib Vzw |
Means and method for diagnosis and treatment of alzheimer's disease
|
|
WO2013121042A1
(en)
|
2012-02-16 |
2013-08-22 |
Vib Vzw |
PP2A SUBUNITS IN DNA REPAIR, THE PP2A B55α SUBUNIT AS NOVEL PHD2 INTERACTING PROTEIN, AND IMPLICATIONS FOR CANCER
|
|
CA2865506C
(en)
|
2012-03-15 |
2021-07-06 |
Omeros Corporation |
Composition and method for diversification of target sequences
|
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
|
MX360110B
(es)
|
2012-04-20 |
2018-10-23 |
Merus Nv |
Metodos y medios para la produccion de moleculas de tipo ig.
|
|
ES2715279T3
(es)
|
2012-05-24 |
2019-06-03 |
Vib Vzw |
Dominios variables individuales inmunoglobulínicos anti-receptor de manosa de macrófagos para elegir como diana y obtener imágenes in vivo de macrófagos asociados a tumores
|
|
US11339208B1
(en)
|
2012-05-31 |
2022-05-24 |
United States Of America As Represented By The Secretary Of The Air Force |
Camelidae single-domain antibodies against Yersinia pestis and methods of use
|
|
EP2687595B1
(de)
|
2012-07-19 |
2018-05-30 |
Laboratoire Français du Fractionnement et des Biotechnologies |
Verfahren zur Reinigung eines transgenen Faktor VII
|
|
CA2880007C
(en)
|
2012-07-25 |
2021-12-28 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
|
ES2647082T3
(es)
|
2012-07-31 |
2017-12-19 |
Bioasis Technologies Inc |
Proteínas desfosforiladas de la enfermedad de depósito lisosómico y métodos de uso de las mismas
|
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
|
ES2822135T3
(es)
|
2012-10-18 |
2021-04-29 |
Univ Rockefeller |
Anticuerpos anti-VIH ampliamente neutralizantes
|
|
EP3925977A1
(de)
|
2012-10-30 |
2021-12-22 |
Apexigen, Inc. |
Anti-cd40-antikörper und verfahren zur verwendung
|
|
WO2014087010A1
(en)
|
2012-12-07 |
2014-06-12 |
Ablynx N.V. |
IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
|
|
JP2016505843A
(ja)
|
2012-12-19 |
2016-02-25 |
アンプリミューン， インコーポレイテッド |
Ｂ７−ｈ４特異的抗体、並びにその組成物及び使用方法
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
US9790277B2
(en)
|
2012-12-21 |
2017-10-17 |
The Johns Hopkins University |
Anti-H7CR antibodies
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
WO2014118297A1
(en)
|
2013-01-30 |
2014-08-07 |
Vib Vzw |
Novel chimeric polypeptides for screening and drug discovery purposes
|
|
WO2014122144A1
(en)
|
2013-02-05 |
2014-08-14 |
Engmab Ag |
BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA
|
|
EP2762496A1
(de)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Verfahren zur Auswahl von Antikörpern gegen BCMA
|
|
EP2953973B1
(de)
|
2013-02-05 |
2019-07-10 |
VIB vzw |
Muskarinische acetylcholinrezeptorbinder und verwendungen davon
|
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
|
WO2014133855A1
(en)
|
2013-02-28 |
2014-09-04 |
Caprion Proteomics Inc. |
Tuberculosis biomarkers and uses thereof
|
|
WO2014160438A1
(en)
|
2013-03-13 |
2014-10-02 |
Bioasis Technologies Inc. |
Fragments of p97 and uses thereof
|
|
EP2970479B1
(de)
|
2013-03-14 |
2019-04-24 |
Novartis AG |
Antikörper gegen notch 3
|
|
ES2964340T3
(es)
|
2013-03-15 |
2024-04-05 |
Omeros Corp |
Métodos para generar anticuerpos portadores de péptidos bioactivos y composiciones que comprenden los mismos
|
|
US20140363433A1
(en)
|
2013-03-15 |
2014-12-11 |
Omeros Corporation |
Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
|
|
US10238690B2
(en)
|
2013-03-15 |
2019-03-26 |
Celgene Corporation |
Modified T lymphocytes comprising an inducible caspase and methods of apoptosis
|
|
EP2968487B1
(de)
|
2013-03-15 |
2019-01-30 |
Vib Vzw |
Variable einzeldomänen des anti-makrophagen-mannose-rezeptors zur verwendung bei kardiovaskulären erkrankungen
|
|
LT2976361T
(lt)
|
2013-03-18 |
2018-10-25 |
Biocerox Products B.V. |
Humanizuoti antikūnai prieš receptorių cd134 (ox40) ir jų naudojimas
|
|
US10233249B2
(en)
|
2013-03-19 |
2019-03-19 |
Beijing Shenogen Pharma Group Ltd. |
Antibodies and methods for treating estrogen receptor-associated diseases
|
|
EP2789630A1
(de)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispezifische Antikörper gegen CD3e und ROR1
|
|
CN105358698B
(zh)
|
2013-04-29 |
2024-02-20 |
生物催化公司 |
包含结合至鞘脂的抗体的农用化学组合物
|
|
NL1040254C2
(en)
|
2013-05-17 |
2014-11-24 |
Ablynx Nv |
Stable formulations of immunoglobulin single variable domains and uses thereof.
|
|
JP6682426B2
(ja)
|
2013-05-24 |
2020-04-15 |
メディミューン，エルエルシー |
抗ｂ７−ｈ５抗体およびその使用
|
|
WO2014194293A1
(en)
|
2013-05-30 |
2014-12-04 |
Amplimmune, Inc. |
Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
|
|
US10100123B2
(en)
|
2013-06-06 |
2018-10-16 |
Pierre Fabre Medicament |
Anti-C10orf54 antibodies and uses thereof
|
|
CN113683695A
(zh)
|
2013-08-02 |
2021-11-23 |
辉瑞公司 |
抗cxcr4抗体及抗体-药物缀合物
|
|
WO2015021166A2
(en)
|
2013-08-07 |
2015-02-12 |
Alexion Pharmaceuticals, Inc. |
Atypical hemolytic uremic syndrome biomarker proteins
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
WO2015031673A2
(en)
|
2013-08-28 |
2015-03-05 |
Bioasis Technologies Inc. |
Cns-targeted conjugates having modified fc regions and methods of use thereof
|
|
EP2883883A1
(de)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden
|
|
EP4124624A3
(de)
|
2013-12-20 |
2023-05-03 |
Intervet International B.V. |
Antikörper gegen hunde-pd-1
|
|
EP3099707B1
(de)
|
2014-01-30 |
2021-12-29 |
Vib Vzw |
Opioidrezeptorbinder und verwendungen davon
|
|
CA2935195A1
(en)
|
2014-02-03 |
2015-08-06 |
Bioasis Technologies, Inc. |
P97 fusion proteins
|
|
EP3102245B1
(de)
|
2014-02-05 |
2021-09-08 |
Molecular Templates, Inc. |
Verfahren zum abtasten, auswählen und identifizieren von cytotoxischen rekombinanten polypeptiden auf grundlage einer vorläufigen minderung der ribotoxizität
|
|
WO2015126729A1
(en)
|
2014-02-19 |
2015-08-27 |
Bioasis Technologies, Inc. |
P97-ids fusion proteins
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
|
CA2942697A1
(en)
|
2014-03-21 |
2015-09-24 |
Lynn Macdonald |
Non-human animals that make single domain binding proteins
|
|
KR20160141865A
(ko)
|
2014-04-25 |
2016-12-09 |
블루버드 바이오, 인코포레이티드. |
양자 세포 치료제를 제조하는 개선된 방법
|
|
BR112016024481A2
(pt)
|
2014-04-25 |
2017-10-10 |
Bluebird Bio Inc |
receptores quiméricos de antígenos com promotor mnd
|
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
|
EP3137610B1
(de)
|
2014-05-01 |
2019-03-06 |
Bioasis Technologies, Inc. |
P97-polynukleotid-konjugate
|
|
TW202132337A
(zh)
|
2014-05-28 |
2021-09-01 |
美商艾吉納斯公司 |
抗糖皮質素誘導性ｔｎｆｒ家族相關性受體（ｇｉｔｒ）抗體類及使用彼等之方法
|
|
ES2683869T3
(es)
|
2014-05-29 |
2018-09-28 |
Quark Pharmaceuticals, Inc. |
Métodos y composiciones para evitar la lesión por isquemia-reperfusión en órganos
|
|
SG10202108458XA
(en)
|
2014-06-06 |
2021-09-29 |
2Seventy Bio Inc |
Improved t cell compositions
|
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
|
CA2955554C
(en)
|
2014-07-22 |
2022-07-05 |
Vib Vzw |
Methods to select for agents that stabilize protein complexes
|
|
US20170226216A1
(en)
|
2014-07-24 |
2017-08-10 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
|
DK3174559T3
(da)
|
2014-07-29 |
2022-12-05 |
Univ Brussel Vrije |
Radiomærkede antistoffragmenter til anvendelse inden for forebyggelsen og/eller behandlingen af cancer
|
|
US20180036442A1
(en)
|
2014-07-29 |
2018-02-08 |
Vrije Universiteit Brussel |
Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
TWI724997B
(zh)
|
2014-08-19 |
2021-04-21 |
美商默沙東藥廠 |
抗ｔｉｇｉｔ抗體
|
|
AU2015327928A1
(en)
|
2014-10-03 |
2017-05-04 |
Nanotics, Llc |
Compositions and methods for inhibiting the biological activity of soluble biomolecules
|
|
WO2016055592A1
(en)
|
2014-10-09 |
2016-04-14 |
Engmab Ag |
Bispecific antibodies against cd3epsilon and ror1
|
|
EP3215624B1
(de)
|
2014-11-05 |
2023-11-29 |
Biotalys NV |
Transgene pflanzen mit einem für die variable domäne eines schwerkettigen antikörpers codierendem polynukleotid
|
|
PL3333191T3
(pl)
|
2014-12-11 |
2021-05-04 |
Pierre Fabre Médicament |
Przeciwciała przeciwko c10orf54 i ich zastosowania
|
|
PL3628687T3
(pl)
|
2014-12-12 |
2022-03-21 |
2Seventy Bio, Inc. |
Chimeryczne receptory antygenowe bcma
|
|
US20160168237A1
(en)
|
2014-12-12 |
2016-06-16 |
Alexion Pharmaceuticals, Inc. |
Method for treating a complement mediated disorder caused by an infectious agent in a patient
|
|
EP3233910B1
(de)
|
2014-12-19 |
2019-12-11 |
Ablynx N.V. |
Cysteinverknüpfte nanokörperdimere
|
|
EP3237450B1
(de)
|
2014-12-22 |
2021-03-03 |
The Rockefeller University |
Anti-mertk-antikörper und verwendungen davon
|
|
KR102489471B1
(ko)
|
2014-12-30 |
2023-01-18 |
셀진 코포레이션 |
항-cd47 항체 및 그 용도
|
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
|
EP3061826A1
(de)
|
2015-02-27 |
2016-08-31 |
Novartis AG |
Flavivirus-replikons
|
|
SI3265123T1
(sl)
|
2015-03-03 |
2023-02-28 |
Kymab Limited |
Protitelesa, uporabe in postopki
|
|
AU2016233309B2
(en)
|
2015-03-17 |
2021-11-18 |
Memorial Sloan Kettering Cancer Center |
Anti-MUC16 antibodies and uses thereof
|
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
|
EP3274724A1
(de)
|
2015-03-25 |
2018-01-31 |
Alexion Pharmaceuticals, Inc. |
Verfahren zur messung der proteaseaktivität von faktor d des alternativen komplementweges
|
|
ES2721781T3
(es)
|
2015-03-25 |
2019-08-05 |
Alexion Pharma Inc |
Un método para medir la actividad proteasa de C3 y C5 convertasa de la vía de complemento alternativa
|
|
MX2017012662A
(es)
|
2015-03-31 |
2018-05-11 |
Vhsquared Ltd |
Polipeptidos.
|
|
EP3954710A3
(de)
|
2015-04-02 |
2022-07-20 |
Intervet International B.V. |
Antikörper gegen interleukin-4-rezeptor-alpha des hundes
|
|
ES2841437T3
(es)
|
2015-04-13 |
2021-07-08 |
Inst Nat Sante Rech Med |
Métodos y composiciones farmacéuticas para el tratamiento de enfermedades hemorrágicas
|
|
MX2017014188A
(es)
|
2015-05-07 |
2018-04-10 |
Agenus Inc |
Anticuerpos anti-ox40 y metodos para su uso.
|
|
WO2016183183A1
(en)
|
2015-05-11 |
2016-11-17 |
The Johns Hopkins University |
Autoimmune antibodies for use in inhibiting cancer cell growth
|
|
LT3303394T
(lt)
|
2015-05-29 |
2020-10-12 |
Agenus Inc. |
Anti-ctla-4 antikūnai ir jų naudojimo būdai
|
|
WO2016197367A1
(en)
|
2015-06-11 |
2016-12-15 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
JP6432942B2
(ja)
*
|
2015-06-23 |
2018-12-05 |
日立オートモティブシステムズ株式会社 |
ブレーキ装置
|
|
WO2017013026A1
(en)
|
2015-07-17 |
2017-01-26 |
Vrije Universiteit Brussel |
Radiolabelled antibody fragments for use in treating cancer
|
|
BR112018001955B1
(pt)
|
2015-08-03 |
2021-05-11 |
Engmab Sárl |
anticorpo monoclonal que se liga às células b humanas (bcma), composição farmacêutica e seu uso
|
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
EP3334763A4
(de)
|
2015-08-11 |
2019-04-03 |
Wuxi Biologics (Cayman) Inc. |
Neuartige anti-pd-1-antikörper
|
|
CN105063082A
(zh)
*
|
2015-09-07 |
2015-11-18 |
复旦大学 |
用于在***克鲁维酵母营养缺陷型菌株中进行外源基因分泌表达的重组载体
|
|
CN105132452A
(zh)
*
|
2015-09-07 |
2015-12-09 |
复旦大学 |
在马克斯克鲁维酵母营养缺陷型菌株中表达融合了组氨酸标签的外源基因的重组载体
|
|
EP4014996A1
(de)
|
2015-08-31 |
2022-06-22 |
Helixmith Co., Ltd |
Chimäre anti-sialyl-tn-antigenrezeptoren
|
|
EA201890630A1
(ru)
|
2015-09-01 |
2018-10-31 |
Эйдженус Инк. |
Антитела против pd-1 и способы их применения
|
|
AU2016326449A1
(en)
|
2015-09-21 |
2018-03-22 |
Aptevo Research And Development Llc |
CD3 binding polypeptides
|
|
JP6955487B2
(ja)
|
2015-09-24 |
2021-10-27 |
アブビトロ， エルエルシー |
Ｈｉｖ抗体組成物および使用方法
|
|
EP3359566A1
(de)
|
2015-10-07 |
2018-08-15 |
Alexion Pharmaceuticals, Inc. |
Verfahren zur behandlung altersbedingter makuladegeneration bei einem patienten
|
|
US20190177723A1
(en)
|
2015-10-09 |
2019-06-13 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating duchenne muscular dystrophy and related disorders
|
|
US11248055B2
(en)
|
2015-11-27 |
2022-02-15 |
Ablynx N.V. |
Polypeptides inhibiting CD40L
|
|
WO2017099712A1
(en)
|
2015-12-07 |
2017-06-15 |
Bluebird Bio, Inc. |
Improved t cell compositions
|
|
CA3008244A1
(en)
|
2015-12-16 |
2017-06-22 |
Merck Sharp & Dohme Corp. |
Anti-lag3 antibodies and antigen-binding fragments
|
|
US11091556B2
(en)
|
2015-12-18 |
2021-08-17 |
Intervet Inc. |
Caninized human antibodies to human IL-4R alpha
|
|
CN109476756B
(zh)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
一种多特异性Fab融合蛋白及其用途
|
|
WO2017158396A1
(en)
|
2016-03-16 |
2017-09-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cytidine deaminase inhibitors for the treatment of pancreatic cancer
|
|
WO2017162604A1
(en)
|
2016-03-21 |
2017-09-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosis and treatment of solar lentigo
|
|
WO2017161976A1
(en)
|
2016-03-23 |
2017-09-28 |
Mabspace Biosciences (Suzhou) Co., Ltd |
Novel anti-pd-l1 antibodies
|
|
TW201735949A
(zh)
|
2016-03-24 |
2017-10-16 |
千禧製藥公司 |
治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
|
|
WO2017165778A1
(en)
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
|
|
WO2017176762A1
(en)
|
2016-04-06 |
2017-10-12 |
Nanotics, Llc |
Particles comprising subparticles or nucleic acid scaffolds
|
|
JP7125351B2
(ja)
|
2016-04-14 |
2022-08-24 |
２セブンティ バイオ インコーポレイテッド |
サルベージキメラ抗原受容体システム
|
|
EP3445393A4
(de)
|
2016-04-20 |
2020-08-05 |
Merck Sharp & Dohme Corp. |
Cmv-neutralisierende antigenbindende proteine
|
|
WO2017182603A1
(en)
|
2016-04-22 |
2017-10-26 |
Université Libre de Bruxelles |
A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
|
|
WO2017182605A1
(en)
|
2016-04-22 |
2017-10-26 |
Université Libre de Bruxelles |
A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
|
|
EP3452505A1
(de)
|
2016-05-02 |
2019-03-13 |
Ablynx NV |
Behandlung von rsv-infektion
|
|
EP3464360A1
(de)
|
2016-05-27 |
2019-04-10 |
Agenus Inc. |
Anti-tim-3-antikörper und verfahren zur verwendung davon
|
|
WO2018007442A1
(en)
|
2016-07-06 |
2018-01-11 |
Ablynx N.V. |
Treatment of il-6r related diseases
|
|
CA3030099A1
(en)
|
2016-07-08 |
2018-01-11 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
|
TWI765900B
(zh)
|
2016-08-03 |
2022-06-01 |
中國大陸商軒竹（北京）醫藥科技有限公司 |
哌唑黴素(plazomicin)抗體及使用方法
|
|
BR112019002127A2
(pt)
|
2016-08-03 |
2019-09-17 |
Nextcure Inc |
proteína de fusão, vetor, célula, composição farmacêutica, e, uso da proteína de fusão
|
|
WO2018029182A1
(en)
|
2016-08-08 |
2018-02-15 |
Ablynx N.V. |
Il-6r single variable domain antibodies for treatment of il-6r related diseases
|
|
WO2018050833A1
(en)
|
2016-09-15 |
2018-03-22 |
Ablynx Nv |
Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
|
|
EP3515950A4
(de)
|
2016-09-20 |
2020-10-28 |
Wuxi Biologics Ireland Limited. |
Neuartige anti-pcsk9-antikörper
|
|
EP4360714A3
(de)
|
2016-09-21 |
2024-07-24 |
Nextcure, Inc. |
Antikörper für siglec-15 und verfahren zur verwendung davon
|
|
DK3515478T3
(da)
|
2016-09-21 |
2024-05-21 |
Nextcure Inc |
Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
|
|
EP3519438A1
(de)
|
2016-09-30 |
2019-08-07 |
VHsquared Limited |
Zusammensetzungen
|
|
CN117586403A
(zh)
|
2016-10-11 |
2024-02-23 |
艾吉纳斯公司 |
抗lag-3抗体及其使用方法
|
|
JP7256741B2
(ja)
|
2016-10-12 |
2023-04-12 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性
|
|
US11965884B2
(en)
|
2016-10-19 |
2024-04-23 |
Alexion Pharmaceuticals, Inc. |
Method of quantitating unbound C5 in a sample
|
|
WO2018075761A1
(en)
|
2016-10-19 |
2018-04-26 |
Alexion Pharmaceuticals, Inc. |
A method of quantitating unbound c5a in a sample
|
|
US20200057046A1
(en)
|
2016-10-27 |
2020-02-20 |
Alexion Pharmaceuticals, Inc. |
Assay for c5b-9 deposition in complement-associated disorders
|
|
WO2018078083A1
(en)
|
2016-10-28 |
2018-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating multiple myeloma
|
|
ES2908239T3
(es)
|
2016-10-28 |
2022-04-28 |
Astute Medical Inc |
Uso de anticuerpos contra timp-2 para la mejora de la función renal
|
|
CN110167964B
(zh)
|
2016-11-02 |
2023-12-01 |
百时美施贵宝公司 |
组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
|
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
US11332521B2
(en)
|
2016-11-07 |
2022-05-17 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
|
US11840569B2
(en)
|
2016-11-16 |
2023-12-12 |
Ablynx N.V. |
T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
|
|
KR20240046620A
(ko)
|
2016-11-17 |
2024-04-09 |
2세븐티 바이오, 인코포레이티드 |
TGFβ 신호 컨버터
|
|
WO2018099968A1
(en)
|
2016-11-29 |
2018-06-07 |
Ablynx N.V. |
Treatment of infection by respiratory syncytial virus (rsv)
|
|
US10759855B2
(en)
|
2016-12-02 |
2020-09-01 |
Rigel Pharmaceuticals, Inc. |
Antigen binding molecules to TIGIT
|
|
CA3046082A1
(en)
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
MD3551660T2
(ro)
|
2016-12-07 |
2024-03-31 |
Agenus Inc |
Anticorpi anti-CTLA-4 și procedee de utilizare a acestora
|
|
US11613785B2
(en)
|
2017-01-09 |
2023-03-28 |
Onkosxcel Therapeutics, Llc |
Predictive and diagnostic methods for prostate cancer
|
|
WO2018141753A1
(en)
|
2017-01-31 |
2018-08-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating squamous cell carcinomas
|
|
EP3589725A1
(de)
|
2017-02-28 |
2020-01-08 |
Vib Vzw |
Mittel und verfahren zur oralen proteinabgabe
|
|
EP4095161A1
(de)
|
2017-03-15 |
2022-11-30 |
Tsinghua University |
Neuartige anti-trkb-antikörper
|
|
WO2018167283A1
(en)
|
2017-03-17 |
2018-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
|
|
JP7237848B2
(ja)
|
2017-03-27 |
2023-03-13 |
セルジーン コーポレイション |
免疫原性の低下のための方法及び組成物
|
|
WO2018185516A1
(en)
|
2017-04-05 |
2018-10-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
|
|
MX2019012223A
(es)
|
2017-04-13 |
2019-12-09 |
Agenus Inc |
Anticuerpos anti-cd137 y metodos de uso de los mismos.
|
|
WO2018189335A1
(en)
|
2017-04-13 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
|
|
WO2018189403A1
(en)
|
2017-04-14 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancer
|
|
EP3612648A1
(de)
|
2017-04-18 |
2020-02-26 |
Université Libre de Bruxelles |
Biomarker und targets für proliferative erkrankungen
|
|
US20200123238A1
(en)
|
2017-04-19 |
2020-04-23 |
Alexion Pharmaceuticals, Inc. |
Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
|
|
US11767520B2
(en)
|
2017-04-20 |
2023-09-26 |
Atyr Pharma, Inc. |
Compositions and methods for treating lung inflammation
|
|
KR20190141659A
(ko)
|
2017-04-21 |
2019-12-24 |
스태튼 바이오테크놀로지 비.브이. |
항-apoc3 항체 및 이의 사용 방법
|
|
US20220135670A1
(en)
|
2017-04-27 |
2022-05-05 |
Tesaro, Inc. |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
|
CA3062061A1
(en)
|
2017-05-01 |
2018-11-08 |
Agenus Inc. |
Anti-tigit antibodies and methods of use thereof
|
|
WO2018206734A1
(en)
|
2017-05-11 |
2018-11-15 |
Vib Vzw |
Glycosylation of variable immunoglobulin domains
|
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
|
AU2018266562A1
(en)
|
2017-05-12 |
2019-12-05 |
Augusta University Research Institute, Inc. |
Human alpha fetoprotein-specific T cell receptors and uses thereof
|
|
SG10202113337YA
(en)
|
2017-06-02 |
2021-12-30 |
Ablynx Nv |
Aggrecan binding immunoglobulins
|
|
CA3064318A1
(en)
|
2017-06-02 |
2018-12-06 |
Merck Patent Gmbh |
Polypeptides binding adamts5, mmp13 and aggrecan
|
|
CN110997001A
(zh)
|
2017-06-02 |
2020-04-10 |
默克专利股份有限公司 |
Mmp13结合免疫球蛋白
|
|
AU2018277343A1
(en)
|
2017-06-02 |
2020-01-02 |
Ablynx N.V. |
Adamts binding immunoglobulins
|
|
EP3415010A1
(de)
|
2017-06-13 |
2018-12-19 |
Agrosavfe Nv |
Insektenkontrollierende polypeptide und verfahren
|
|
CA3068672A1
(en)
|
2017-06-28 |
2019-01-03 |
The Rockefeller University |
Anti-mertk agonistic antibody-drug conjugates and uses thereof
|
|
MA49565A
(fr)
|
2017-07-11 |
2020-05-20 |
Compass Therapeutics Llc |
Anticorps agonistes qui lient cd137 humain et leurs utilisations
|
|
WO2019012030A1
(en)
|
2017-07-13 |
2019-01-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
|
|
CN111108126B
(zh)
|
2017-07-19 |
2024-04-26 |
非营利性组织佛兰芒综合大学生物技术研究所 |
血清白蛋白结合剂
|
|
WO2019036605A2
(en)
|
2017-08-17 |
2019-02-21 |
Massachusetts Institute Of Technology |
MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
|
|
CN111511762A
(zh)
|
2017-08-21 |
2020-08-07 |
天演药业公司 |
抗cd137分子及其用途
|
|
MX2020002612A
(es)
|
2017-09-07 |
2020-07-13 |
Univ Res Inst Inc Augusta |
Anticuerpos de la proteina de muerte celular programada 1.
|
|
US11230601B2
(en)
|
2017-10-10 |
2022-01-25 |
Tilos Therapeutics, Inc. |
Methods of using anti-lap antibodies
|
|
JP2021502063A
(ja)
|
2017-10-31 |
2021-01-28 |
フエー・イー・ベー・フエー・ゼツト・ウエー |
新規抗原結合性キメラタンパク質とその方法及び使用
|
|
WO2019087115A1
(en)
|
2017-10-31 |
2019-05-09 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
WO2019106126A1
(en)
|
2017-12-01 |
2019-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Mdm2 modulators for the diagnosis and treatment of liposarcoma
|
|
EP3720951A1
(de)
|
2017-12-05 |
2020-10-14 |
Celyad S.A. |
Zusammensetzungen und verfahren zur verbesserung der persistenz von zellen für adoptiven transfer
|
|
US11639496B2
(en)
|
2017-12-05 |
2023-05-02 |
Celyad S.A. |
Reducing fratricide of immune cells expressing NKG2D-based receptors
|
|
US11946094B2
(en)
|
2017-12-10 |
2024-04-02 |
Augusta University Research Institute, Inc. |
Combination therapies and methods of use thereof
|
|
EP3728323A4
(de)
|
2017-12-19 |
2022-01-26 |
Surrozen Operating, Inc. |
Anti-frizzled-antikörper und verfahren zur verwendung
|
|
PE20201339A1
(es)
|
2017-12-19 |
2020-11-25 |
Univ Rockefeller |
Variantes de dominio de fc de igg humana con funcion efectora mejorada
|
|
WO2019126398A1
(en)
|
2017-12-19 |
2019-06-27 |
Surrozen, Inc. |
Wnt surrogate molecules and uses thereof
|
|
WO2019126401A1
(en)
|
2017-12-19 |
2019-06-27 |
Surrozen, Inc. |
Anti-lrp5/6 antibodies and methods of use
|
|
WO2019121872A1
(en)
|
2017-12-20 |
2019-06-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of liver cancer
|
|
CN108218990B
(zh)
|
2017-12-29 |
2021-03-02 |
南京优迈生物科技有限公司 |
分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
|
|
US10899823B2
(en)
|
2018-01-18 |
2021-01-26 |
California Institute Of Technology |
Programmable protein circuits in living cells
|
|
US11965191B2
(en)
|
2018-01-18 |
2024-04-23 |
California Institute Of Technology |
Programmable protein circuits in living cells
|
|
CN112566934A
(zh)
|
2018-01-23 |
2021-03-26 |
奈斯科尔公司 |
B7-h4抗体及其使用方法
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
WO2019148444A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
|
US11802303B2
(en)
|
2018-02-07 |
2023-10-31 |
Georgia Tech Research Corporation |
Methods for multiplexed cell isolation using DNA gates
|
|
WO2019155041A1
(en)
|
2018-02-12 |
2019-08-15 |
Vib Vzw |
Gβγ COMPLEX ANTIBODIES AND USES THEREOF
|
|
JP2021514649A
(ja)
|
2018-03-01 |
2021-06-17 |
ブレイエ・ユニバージテイト・ブリュッセルＶｒｉｊｅ Ｕｎｉｖｅｒｓｉｔｅｉｔ Ｂｒｕｓｓｅｌ |
ヒトｐｄ−ｌ１結合免疫グロブリン
|
|
US20210002373A1
(en)
|
2018-03-01 |
2021-01-07 |
Nextcure, Inc. |
KLRG1 Binding Compositions and Methods of Use Thereof
|
|
NL2020520B1
(en)
|
2018-03-02 |
2019-09-12 |
Labo Bio Medical Invest B V |
Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
|
|
BR112020018480B1
(pt)
|
2018-03-14 |
2022-09-27 |
Surface Oncology, Inc |
Usos de anticorpos que se ligam a cd39 no tratamento de câncer
|
|
EP3768720A4
(de)
|
2018-03-20 |
2022-01-05 |
Wuxi Biologics Ireland Limited |
Neuartiges anti-lag-3-antikörper-polypeptid
|
|
CA3093740A1
(en)
|
2018-03-22 |
2019-09-26 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
|
CA3088676A1
(en)
|
2018-03-23 |
2019-09-26 |
Universite Libre De Bruxelles |
Wnt signaling agonist molecules
|
|
MX2020010091A
(es)
|
2018-03-27 |
2021-01-15 |
Umc Utrecht Holding Bv |
Trombolisis direccionada para tratamiento de trombosis microvascular.
|
|
US20210047696A1
(en)
|
2018-03-28 |
2021-02-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
|
US20210164984A1
(en)
|
2018-04-13 |
2021-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
|
|
WO2019211370A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
|
WO2019211369A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
|
US20190345261A1
(en)
|
2018-05-10 |
2019-11-14 |
Sensei Biotherapeutics, Inc. |
Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
|
|
KR20240056644A
(ko)
|
2018-05-10 |
2024-04-30 |
주식회사 뉴라클사이언스 |
서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
|
|
WO2019234099A1
(en)
|
2018-06-06 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
|
|
WO2019234221A1
(en)
|
2018-06-08 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
WO2019241685A1
(en)
|
2018-06-14 |
2019-12-19 |
Bluebird Bio, Inc. |
Cd79a chimeric antigen receptors
|
|
US11884729B2
(en)
|
2018-06-29 |
2024-01-30 |
ApitBio, Inc |
Anti-L1CAM antibodies and uses thereof
|
|
US11845797B2
(en)
|
2018-07-03 |
2023-12-19 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
JP2021530483A
(ja)
|
2018-07-11 |
2021-11-11 |
セルジーン コーポレイション |
抗ｂｃｍａキメラ抗原受容体の使用
|
|
WO2020016160A1
(en)
|
2018-07-16 |
2020-01-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat neurological diseases
|
|
WO2020016377A1
(en)
|
2018-07-19 |
2020-01-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination for treating cancer
|
|
AU2019306165A1
(en)
|
2018-07-20 |
2021-02-25 |
Pierre Fabre Medicament |
Receptor for vista
|
|
WO2020023300A1
(en)
|
2018-07-22 |
2020-01-30 |
Bioasis Technologies, Inc. |
Treatment of lymmphatic metastases
|
|
US20210186880A1
(en)
|
2018-08-03 |
2021-06-24 |
Brown University |
Oral formulations with increased uptake
|
|
US20210388089A1
(en)
|
2018-08-09 |
2021-12-16 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
|
US20210309746A1
(en)
|
2018-08-09 |
2021-10-07 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
|
US11453893B2
(en)
|
2018-08-30 |
2022-09-27 |
California Institute Of Technology |
RNA-based delivery systems with levels of control
|
|
WO2020047320A1
(en)
|
2018-08-31 |
2020-03-05 |
California Institute Of Technology |
Synthetic protein circuits detecting signal transducer activity
|
|
KR20210056344A
(ko)
|
2018-09-04 |
2021-05-18 |
난징 유엠에이비-바이오파마 컴퍼티 리미티드 |
융합 단백질 및 그가 종양 및/또는 바이러스 감염을 치료하기 위한 약물 제조에서의 응용
|
|
CN112771071A
(zh)
|
2018-09-28 |
2021-05-07 |
麻省理工学院 |
胶原蛋白定位的免疫调节分子及其方法
|
|
WO2020070678A2
(en)
|
2018-10-03 |
2020-04-09 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
|
|
CN113164780A
(zh)
|
2018-10-10 |
2021-07-23 |
泰洛斯治疗公司 |
抗lap抗体变体及其用途
|
|
WO2020086742A1
(en)
|
2018-10-24 |
2020-04-30 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
|
EP3870608A1
(de)
|
2018-10-25 |
2021-09-01 |
Polpharma Biologics Utrecht B.V. |
Anti-human-cd89-antikörper und verwendungen davon
|
|
US20220000893A1
(en)
|
2018-10-31 |
2022-01-06 |
|Nserm (Institut National De La Santé Et De La Recherche Médicale) |
Method for treating t-helper type 2 mediated disease
|
|
EP3877399A4
(de)
|
2018-11-06 |
2022-10-19 |
Alsatech, Inc. |
Zellbasierte gentherapie für neurodegenerative erkrankungen
|
|
US11046769B2
(en)
|
2018-11-13 |
2021-06-29 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
|
US20220026445A1
(en)
|
2018-12-07 |
2022-01-27 |
Georgia Tech Research Corporation |
Antibodies that bind to natively folded myocilin
|
|
US11667676B2
(en)
|
2019-01-10 |
2023-06-06 |
California Institute Of Technology |
Synthetic system for tunable thresholding of protein signals
|
|
JP2022522265A
(ja)
|
2019-01-16 |
2022-04-15 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
エリスロフェロンの変異体及びその使用
|
|
CN113474371A
(zh)
|
2019-01-16 |
2021-10-01 |
指南针制药有限责任公司 |
与人cd137结合的抗体的制剂及其用途
|
|
EP3924389A4
(de)
|
2019-02-15 |
2023-06-14 |
Integral Molecular, Inc. |
Claudin-6-antikörper und deren verwendungen
|
|
CN113661175A
(zh)
|
2019-02-15 |
2021-11-16 |
整体分子公司 |
包含共同轻链的抗体及其用途
|
|
JP2022522344A
(ja)
|
2019-02-26 |
2022-04-18 |
インスピアーナ， インコーポレイテッド |
高親和性抗ｍｅｒｔｋ抗体およびその使用
|
|
JP2022523781A
(ja)
|
2019-03-01 |
2022-04-26 |
アロジーン セラピューティクス，インコーポレイテッド |
Ｄｌｌ３標的化キメラ抗原受容体および結合剤
|
|
BR112021017744A2
(pt)
|
2019-03-08 |
2021-11-16 |
Obsidian Therapeutics Inc |
Composições e métodos de cd40l para regulação ajustável
|
|
CN113874392A
(zh)
|
2019-03-28 |
2021-12-31 |
丹尼斯科美国公司 |
工程化抗体
|
|
WO2020193740A1
(en)
|
2019-03-28 |
2020-10-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy for treating pancreatic cancer
|
|
WO2020208082A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating cmv related diseases
|
|
AU2020266750A1
(en)
|
2019-04-29 |
2021-11-25 |
Confo Therapeutics N.V. |
Screening methods and assays for use with transmembrane proteins, in particular with GPCRS
|
|
US20220289837A1
(en)
|
2019-04-30 |
2022-09-15 |
Vib Vzw |
Cystic Fibrosis Transmembrane Conductance Regulator Stabilizing Agents
|
|
US20200363400A1
(en)
|
2019-05-13 |
2020-11-19 |
Regeneron Pharmaceuticals, Inc. |
Competitive Ligand Binding Assays
|
|
JP2022533591A
(ja)
|
2019-05-14 |
2022-07-25 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
リンホトキシンアルファ遮断剤によりターゲットされた制御性ｔ細胞及びその使用
|
|
US20220227859A1
(en)
|
2019-05-16 |
2022-07-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat type 2 inflammation or mast-cell dependent disease
|
|
WO2020239934A1
(en)
|
2019-05-28 |
2020-12-03 |
Vib Vzw |
Cd8+ t-cells lacking plexins and their application in cancer treatment
|
|
WO2020239945A1
(en)
|
2019-05-28 |
2020-12-03 |
Vib Vzw |
Cancer treatment by targeting plexins in the immune compartment
|
|
KR20220016943A
(ko)
|
2019-06-04 |
2022-02-10 |
바이오세우스 인크. |
항 씨이에이씨에이엠5 단클론 항체 및 그의 제조 방법 및 그의 용도
|
|
MX2021015762A
(es)
|
2019-06-21 |
2022-04-18 |
Sorriso Pharmaceuticals Inc |
Composiciones.
|
|
US20220242945A1
(en)
|
2019-06-21 |
2022-08-04 |
Sorriso Pharmaceuticals, Inc. |
Polypeptides
|
|
AU2020294980A1
(en)
|
2019-06-21 |
2022-02-17 |
Sorriso Pharmaceuticals, Inc. |
Polypeptides
|
|
US11642409B2
(en)
|
2019-06-26 |
2023-05-09 |
Massachusetts Insttute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
WO2021001539A1
(en)
|
2019-07-04 |
2021-01-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy to detect and treat eosinophilic fasciitis
|
|
CA3145345A1
(en)
|
2019-07-15 |
2021-01-21 |
Intervet International B.V. |
Caninized antibodies against canine ctla-4
|
|
KR20220053007A
(ko)
|
2019-08-30 |
2022-04-28 |
아게누스 인코포레이티드 |
항-cd96 항체 및 이의 사용 방법
|
|
US20220340975A1
(en)
|
2019-09-05 |
2022-10-27 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Method of treatment and pronostic of acute myeloid leukemia
|
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
|
CA3145940A1
(en)
|
2019-09-16 |
2021-03-25 |
Scott Chappel |
Anti-cd39 antibody compositions and methods
|
|
CN115087671A
(zh)
|
2019-09-25 |
2022-09-20 |
表面肿瘤学公司 |
抗il-27抗体及其用途
|
|
TW202126295A
(zh)
|
2019-09-27 |
2021-07-16 |
大陸商江蘇挪貝肽醫藥科技有限公司 |
一種治療心境障礙的方法
|
|
WO2021058744A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of müllerian inhibiting substance inhibitors for treating cancer
|
|
EP4048703A1
(de)
|
2019-10-21 |
2022-08-31 |
Vib Vzw |
Nanoscheibenspezifische antigenbindende chimäre proteine
|
|
WO2021080682A1
(en)
|
2019-10-24 |
2021-04-29 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human cd161 and uses thereof
|
|
US20240148901A1
(en)
|
2019-10-28 |
2024-05-09 |
Georgia Tech Research Corporation |
Compositions and methods for prophylaxis of hiv
|
|
WO2021086948A1
(en)
|
2019-10-28 |
2021-05-06 |
Georgia Tech Research Corporation |
Mrna-encoded antibodies for contraception
|
|
AU2020377930A1
(en)
|
2019-11-05 |
2022-05-19 |
Bristol-Myers Squibb Company |
Uses of anti-BCMA chimeric antigen receptors
|
|
US20220386594A1
(en)
|
2019-11-11 |
2022-12-08 |
Ibi-Ag Innovative Bio Insecticides Ltd. |
Insect control nanobodies and uses thereof
|
|
WO2021105391A1
(en)
|
2019-11-27 |
2021-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination comprising nupr1 inhibitors to treat cancer
|
|
WO2021105384A1
(en)
|
2019-11-27 |
2021-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Targeting the nls region of nupr1 protein to treat cancer
|
|
EP4065603A1
(de)
|
2019-11-27 |
2022-10-05 |
Vib Vzw |
Positive allosterische modulatoren des calciumempfindlichen rezeptors
|
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
|
GB201918279D0
(en)
|
2019-12-12 |
2020-01-29 |
Vib Vzw |
Glycosylated single chain immunoglobulin domains
|
|
WO2021123360A1
(en)
|
2019-12-20 |
2021-06-24 |
Vib Vzw |
Nanobody exchange chromatography
|
|
BR112022012725A2
(pt)
|
2019-12-24 |
2022-11-16 |
Jjp Biologics Sp Z O O |
Anticorpos hvem (tnfrsf14) anti-humanos e usos dos mesmos
|
|
MX2022008341A
(es)
|
2020-01-06 |
2022-08-10 |
Vaccinex Inc |
Anticuerpos anti-ccr8 y usos de estos.
|
|
WO2021140205A1
(en)
|
2020-01-10 |
2021-07-15 |
Confo Therapeutics N.V. |
Methods for generating antibodies and antibody fragments and libraries comprising same
|
|
WO2021156490A2
(en)
|
2020-02-06 |
2021-08-12 |
Vib Vzw |
Corona virus binders
|
|
IL295891A
(en)
|
2020-02-24 |
2022-10-01 |
Immatics Us Inc |
Methods for propagating t cells for the treatment of cancer and related malignancies
|
|
CN115698047A
(zh)
|
2020-02-25 |
2023-02-03 |
非营利性组织佛兰芒综合大学生物技术研究所 |
富含亮氨酸的重复激酶2变构调节剂
|
|
KR20220167276A
(ko)
|
2020-03-10 |
2022-12-20 |
매사추세츠 인스티튜트 오브 테크놀로지 |
NPM1c-양성 암의 면역치료를 위한 조성물 및 방법
|
|
WO2021183675A2
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Methods for generating engineered memory-like nk cells and compositions thereof
|
|
DE102020111571A1
(de)
|
2020-03-11 |
2021-09-16 |
Immatics US, Inc. |
Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
|
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
|
WO2021198260A1
(en)
|
2020-03-30 |
2021-10-07 |
Ablynx Nv |
Method for the production and purification of multivalent immunoglobulin single variable domains
|
|
CA3178461A1
(en)
|
2020-03-31 |
2021-10-07 |
Biotalys NV |
Anti-fungal polypeptides
|
|
CN113461817A
(zh)
|
2020-03-31 |
2021-10-01 |
苏州泽璟生物制药股份有限公司 |
一种抗人cd47抗体及其抗原结合片段、制备方法和应用
|
|
EP4132971A1
(de)
|
2020-04-09 |
2023-02-15 |
Merck Sharp & Dohme LLC |
Affinitätsgereifte anti-lap-antikörper und verwendungen davon
|
|
US20230416344A1
(en)
|
2020-04-16 |
2023-12-28 |
Alexion Pharmaceuticals, Inc. |
Methods for treating a complement mediated disorder caused by viruses
|
|
WO2021215919A1
(en)
|
2020-04-21 |
2021-10-28 |
Polpharma Biologics Utrecht B.V. |
Humanized anti-human cd89 antibodies and uses thereof
|
|
CN113527488A
(zh)
|
2020-04-22 |
2021-10-22 |
迈威(上海)生物科技股份有限公司 |
一种靶向人程序性死亡配体1（pd-l1）的单可变域抗体及其衍生物
|
|
WO2021224913A1
(en)
|
2020-05-04 |
2021-11-11 |
Immunorizon Ltd. |
Precursor tri-specific antibody constructs and methods of use thereof
|
|
WO2021229104A1
(en)
|
2020-05-15 |
2021-11-18 |
Université de Liège |
Anti-cd38 single-domain antibodies in disease monitoring and treatment
|
|
US20210355468A1
(en)
|
2020-05-18 |
2021-11-18 |
Bioasis Technologies, Inc. |
Compositions and methods for treating lewy body dementia
|
|
EP4153192B1
(de)
|
2020-05-19 |
2024-07-24 |
Institut Curie |
Antagonist des cd44/hyaluronsäure-wegs zur verwendung in einem verfahren zur behandlung des zytokinfreisetzungssyndroms
|
|
MX2022015157A
(es)
|
2020-06-02 |
2023-01-16 |
Arcus Biosciences Inc |
Anticuerpos para tigit.
|
|
US20210393787A1
(en)
|
2020-06-17 |
2021-12-23 |
Bioasis Technologies, Inc. |
Compositions and methods for treating frontotemporal dementia
|
|
WO2021255204A1
(en)
|
2020-06-18 |
2021-12-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy for treating pancreatic cancer
|
|
WO2022003156A1
(en)
|
2020-07-02 |
2022-01-06 |
Oncurious Nv |
Ccr8 non-blocking binders
|
|
EP4189061A1
(de)
|
2020-07-31 |
2023-06-07 |
Biotalys NV |
Verfahren zur erhöhung der ausbeute rekombinanter proteine
|
|
WO2022040631A1
(en)
|
2020-08-21 |
2022-02-24 |
Immatics US, Inc. |
Methods for isolating cd8+ selected t cells
|
|
WO2022060806A1
(en)
|
2020-09-16 |
2022-03-24 |
Obsidian Therapeutics, Inc. |
Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
|
|
WO2022063957A1
(en)
|
2020-09-24 |
2022-03-31 |
Vib Vzw |
Biomarker for anti-tumor therapy
|
|
EP4216943A1
(de)
|
2020-09-24 |
2023-08-02 |
Vib Vzw |
Kombination von p2y6-inhibitoren und immuncheckpoint-inhibitoren
|
|
JP2023544124A
(ja)
|
2020-09-25 |
2023-10-20 |
アブリンクス エン．ヴェー． |
Ｉｌ－１３およびｏｘ４０ｌを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
|
|
US20230416346A1
(en)
|
2020-10-21 |
2023-12-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
C-terminal sparc fragments for treating cancer
|
|
KR20230133837A
(ko)
|
2020-11-04 |
2023-09-19 |
마이얼로이드 테라퓨틱스, 인크. |
조작된 키메라 융합 단백질 조성물 및 그의 사용 방법
|
|
WO2022098685A2
(en)
|
2020-11-04 |
2022-05-12 |
Celgene Corporation |
Car t cell therapy in patients who have had prior anti-cancer alkylator therapy
|
|
EP4255929A2
(de)
|
2020-12-02 |
2023-10-11 |
Vib Vzw |
Ltbr-agonist in kombinationstherapie gegen krebs
|
|
WO2022117569A1
(en)
|
2020-12-02 |
2022-06-09 |
Oncurious Nv |
A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
|
|
CN116888474A
(zh)
|
2020-12-04 |
2023-10-13 |
细胞基因公司 |
嵌合抗原受体(car)t细胞疗法与炎症相关可溶性因子抑制剂的组合用途
|
|
US11897951B2
(en)
|
2020-12-18 |
2024-02-13 |
Ablynx N.V. |
Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
|
|
GB202020502D0
(en)
|
2020-12-23 |
2021-02-03 |
Vib Vzw |
Antibody composistion for treatment of corona virus infection
|
|
US20240052045A1
(en)
|
2020-12-24 |
2024-02-15 |
Vib Vzw |
Murine cross-reactive human ccr8 binders
|
|
EP4267618A1
(de)
|
2020-12-24 |
2023-11-01 |
Vib Vzw |
Nichtblockierende, menschliche ccr8-bindemittel
|
|
WO2022136647A1
(en)
|
2020-12-24 |
2022-06-30 |
Oncurious Nv |
Human ccr8 binders
|
|
JP2024504875A
(ja)
|
2021-02-01 |
2024-02-01 |
▲い▼尊生物医薬（浙江）有限公司 |
標的タンパク質分解システムおよびその応用
|
|
KR20230141853A
(ko)
|
2021-02-05 |
2023-10-10 |
브이아이비 브이지더블유 |
사베코바이러스 결합제
|
|
CN117794566A
(zh)
|
2021-02-05 |
2024-03-29 |
Vib研究所 |
沙贝病毒结合剂
|
|
US20240229154A9
(en)
|
2021-02-12 |
2024-07-11 |
Institut National de la Santé et de la Recherche Médicale |
Method for prognosis and treating a patient suffering from cancer
|
|
WO2022175392A1
(en)
|
2021-02-17 |
2022-08-25 |
Vib Vzw |
Inhibition of slc4a4 in the treatment of cancer
|
|
IL305318A
(en)
|
2021-02-19 |
2023-10-01 |
Vib Vzw |
Cation-independent mannose-6-phosphate receptor binders
|
|
EP4308133A2
(de)
|
2021-03-17 |
2024-01-24 |
Myeloid Therapeutics, Inc. |
Manipulierte chimäre fusionsproteinzusammensetzungen und verfahren zur verwendung davon
|
|
WO2022199804A1
(en)
|
2021-03-24 |
2022-09-29 |
Vib Vzw |
Nek6 inhibition to treat als and ftd
|
|
WO2022212876A1
(en)
|
2021-04-02 |
2022-10-06 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
CN117597359A
(zh)
|
2021-04-08 |
2024-02-23 |
马伦戈治疗公司 |
与tcr结合的多功能分子及其用途
|
|
EP4322937A1
(de)
|
2021-04-14 |
2024-02-21 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Neues verfahren zur verbesserung der antitumoraktivität von makrophagen
|
|
US20240228659A1
(en)
|
2021-04-14 |
2024-07-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve nk cells cytotoxicity
|
|
WO2022221737A1
(en)
|
2021-04-16 |
2022-10-20 |
Juno Therapeutics, Inc. |
T cell therapy in patients who have had prior stem cell transplant
|
|
IL308198A
(en)
|
2021-05-07 |
2024-01-01 |
Surface Oncology Llc |
Anti-IL-27 antibodies and uses thereof
|
|
WO2022242892A1
(en)
|
2021-05-17 |
2022-11-24 |
Université de Liège |
Anti-cd38 single-domain antibodies in disease monitoring and treatment
|
|
WO2022253910A1
(en)
|
2021-06-02 |
2022-12-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A new method to treat an inflammatory skin disease
|
|
WO2022261846A1
(zh)
|
2021-06-16 |
2022-12-22 |
上海鑫湾生物科技有限公司 |
靶向axl蛋白的抗体及其抗原结合片段、其制备方法和应用
|
|
JP2024523921A
(ja)
|
2021-06-23 |
2024-07-02 |
フエー・イー・ベー・フエー・ゼツト・ウエー |
特異的バインダーの選択手段及び方法
|
|
WO2023274183A1
(zh)
|
2021-06-29 |
2023-01-05 |
江苏先声药业有限公司 |
Cd16抗体及其应用
|
|
EP4378954A1
(de)
|
2021-07-30 |
2024-06-05 |
Shandong Simcere Biopharmaceutical Co., Ltd. |
Bispezifischer anti-pvrig/anti-tigit-antikörper und anwendung
|
|
EP4377352A2
(de)
|
2021-07-30 |
2024-06-05 |
Vib Vzw |
Kationunabhängige mannose-6-phosphat-rezeptorbindemittel für gezielten proteinabbau
|
|
CN118019548A
(zh)
|
2021-08-06 |
2024-05-10 |
蒙彼利埃癌症研究所 |
用于治疗癌症的方法
|
|
WO2023041744A1
(en)
|
2021-09-17 |
2023-03-23 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
|
EP4405680A1
(de)
|
2021-09-20 |
2024-07-31 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren zur verbesserung der wirksamkeit einer hdac-hemmertherapie und vorhersage der reaktion auf die behandlung mit hdac-hemmer
|
|
WO2023057484A1
(en)
|
2021-10-06 |
2023-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
|
|
WO2023057601A1
(en)
|
2021-10-06 |
2023-04-13 |
Biotalys NV |
Anti-fungal polypeptides
|
|
WO2023061005A1
(zh)
|
2021-10-14 |
2023-04-20 |
徕特康(苏州)生物制药有限公司 |
新型抗体-细胞因子融合蛋白及其制备方法和用途
|
|
WO2023073099A1
(en)
|
2021-10-28 |
2023-05-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to improve phagocytosis
|
|
WO2023078906A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating acute myeloid leukemia
|
|
EP4180518A1
(de)
|
2021-11-12 |
2023-05-17 |
Istituto Europeo di Oncologia S.r.l. |
T-zellen und deren verwendungen
|
|
WO2023089032A1
(en)
|
2021-11-19 |
2023-05-25 |
Institut Curie |
Methods for the treatment of hrd cancer and brca-associated cancer
|
|
WO2023089159A1
(en)
|
2021-11-22 |
2023-05-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy targeting stroma/tumor cell crosstalk to treat a cancer
|
|
WO2023099763A1
(en)
|
2021-12-03 |
2023-06-08 |
Institut Curie |
Sirt6 inhibitors for use in treating resistant hrd cancer
|
|
WO2023098846A1
(zh)
|
2021-12-03 |
2023-06-08 |
江苏先声药业有限公司 |
抗bcma纳米抗体及其应用
|
|
AU2022409802A1
(en)
|
2021-12-15 |
2024-06-06 |
Interius Biotherapeutics, Inc. |
Pseudotyped viral particles, compositions comprising the same, and uses thereof
|
|
CA3242445A1
(en)
|
2021-12-17 |
2023-06-22 |
Ablynx N.V. |
Polypeptides comprising immunoglobulin single variable domains targeting tcras, cd33 and cd123
|
|
WO2023125888A1
(zh)
|
2021-12-31 |
2023-07-06 |
山东先声生物制药有限公司 |
一种gprc5d抗体及其应用
|
|
WO2023135198A1
(en)
|
2022-01-12 |
2023-07-20 |
Vib Vzw |
Human ntcp binders for therapeutic use and liver-specific targeted delivery
|
|
WO2023148291A1
(en)
|
2022-02-02 |
2023-08-10 |
Biotalys NV |
Methods for genome editing
|
|
WO2023148397A1
(en)
|
2022-02-07 |
2023-08-10 |
Vib Vzw |
Engineered stabilizing aglycosylated fc-regions
|
|
WO2023151894A1
(en)
|
2022-02-11 |
2023-08-17 |
Henkel Ag & Co. Kgaa |
Process for the synthesis of alpha-methylene-gamma-butyrolactone
|
|
WO2023164487A1
(en)
|
2022-02-22 |
2023-08-31 |
Brown University |
Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
|
|
WO2023183477A1
(en)
|
2022-03-23 |
2023-09-28 |
Bodhi Bio Llc |
Compositions and methods for antigen-specific therapy
|
|
WO2023198848A1
(en)
|
2022-04-13 |
2023-10-19 |
Vib Vzw |
An ltbr agonist in combination therapy against cancer
|
|
TW202409083A
(zh)
|
2022-05-02 |
2024-03-01 |
美商阿克思生物科學有限公司 |
抗-tigit抗體及其用途
|
|
WO2023213751A1
(en)
|
2022-05-02 |
2023-11-09 |
Umc Utrecht Holding B.V |
Single domain antibodies for the detection of plasmin-cleaved vwf
|
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
|
WO2023222825A1
(en)
|
2022-05-18 |
2023-11-23 |
Vib Vzw |
Sarbecovirus spike s2 subunit binders
|
|
US20230372395A1
(en)
|
2022-05-19 |
2023-11-23 |
Massachusetts Institute Of Technology |
Car cells targeting an inserted ligand
|
|
US20240025987A1
(en)
|
2022-05-25 |
2024-01-25 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
WO2023230128A1
(en)
|
2022-05-25 |
2023-11-30 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
|
WO2023240109A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|
|
WO2024008755A1
(en)
|
2022-07-04 |
2024-01-11 |
Vib Vzw |
Blood-cerebrospinal fluid barrier crossing antibodies
|
|
US20240117038A1
(en)
|
2022-07-18 |
2024-04-11 |
Ablynx N.V. |
Cx3cr1-binding compounds, methods and uses thereof
|
|
WO2024028476A1
(en)
|
2022-08-05 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of th2-mediated diseases
|
|
WO2024037910A1
(en)
|
2022-08-17 |
2024-02-22 |
Institut National de la Santé et de la Recherche Médicale |
Syk inhibitors for use in the treatment of cancer
|
|
WO2024050524A1
(en)
|
2022-09-01 |
2024-03-07 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
|
|
WO2024054436A1
(en)
|
2022-09-06 |
2024-03-14 |
Alexion Pharmaceuticals, Inc. |
Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
|
|
WO2024068744A1
(en)
|
2022-09-27 |
2024-04-04 |
Vib Vzw |
Antivirals against human parainfluenza virus
|
|
WO2024105091A1
(en)
|
2022-11-15 |
2024-05-23 |
Imec Vzw |
Method and system for droplet manipulation
|
|
WO2024118593A1
(en)
|
2022-11-28 |
2024-06-06 |
Allogene Therapeutics Inc. |
Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof
|
|
WO2024126805A1
(en)
|
2022-12-15 |
2024-06-20 |
Aarhus Universitet |
Synthetic activation of multimeric transmembrane receptors
|
|
WO2024133723A1
(en)
|
2022-12-22 |
2024-06-27 |
Institut National de la Santé et de la Recherche Médicale |
Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
|
|
WO2024133937A1
(en)
|
2022-12-22 |
2024-06-27 |
Biotalys NV |
Methods for genome editing
|
|
WO2024145551A1
(en)
|
2022-12-29 |
2024-07-04 |
Biotalys NV |
Agrochemical compositions
|
|
WO2024141645A1
(en)
|
2022-12-30 |
2024-07-04 |
Biotalys N.V. |
Agglomerate
|
|
WO2024141641A2
(en)
|
2022-12-30 |
2024-07-04 |
Biotalys NV |
Secretion signals
|
|
WO2024141638A1
(en)
|
2022-12-30 |
2024-07-04 |
Biotalys NV |
Self-emulsifiable concentrate
|
|
WO2024148240A1
(en)
|
2023-01-06 |
2024-07-11 |
Lassen Therapeutics 1, Inc. |
ANTI-IL-11Rα ANTIBODIES FOR TREATING THYROID EYE DISEASE
|
|
WO2024148241A1
(en)
|
2023-01-06 |
2024-07-11 |
Lassen Therapeutics 1, Inc. |
Anti-il-18bp antibodies
|